C12N 2770/24034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/24034 (Use of virus or viral component as vaccine) appears on 41 US grants and 53 published applications in this corpus.
Search patents in C12N- Granted patents
- 41
- Published applications
- 53
- Assignees
- 37
- Inventors
- 130
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 3 |
| 2016 | 0 | 1 |
| 2017 | 2 | 2 |
| 2018 | 4 | 9 |
| 2019 | 6 | 5 |
| 2020 | 4 | 7 |
| 2021 | 4 | 5 |
| 2022 | 5 | 1 |
| 2023 | 4 | 6 |
| 2024 | 2 | 5 |
| 2025 | 1 | 0 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for stabilizing flaviviruses with improved formulations15 Sep 2026US 12,734,230 B2Takeda Vaccines, Inc.
- Vaccines against Zika virus23 Sep 2025US 12,419,945 B2The Trustees of the University of Pennsylvania
- Zika vaccines and immunogenic compositions, and methods of using the same8 Oct 2024US 12,109,260 B2Takeda Vaccines, Inc.
- Method for inactivating zika virus and for determining the completeness of inactivation23 Apr 2024US 11,964,008 B2Takeda Vaccines, Inc.
- Zika vaccines and immunogenic compositions, and methods of using the same22 Aug 2023US 11,730,802 B2Takeda Vaccines, Inc.
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
- Dengue vaccine unit dose and administration thereof25 Jun 2026US 2026/0174812 A1Takeda Vaccines, Inc.
- Tropical disease vaccines7 Nov 2024US 2024/0366745 A1ModernaTX, Inc.
- Recombinant classical swine fever virus e2 protein24 Oct 2024US 2024/0350610 A1Boehringer Ingelheim Vetmedica (China) Co., Ltd.
- Method for inactivating zika virus and for determining the completeness of inactivation3 Oct 2024US 2024/0325518 A1Takeda Vaccines, Inc.
Most cited
By later US patents
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Zika virus RNA vaccines108US 10,124,055 B2ModernaTX, Inc. · 2018
- High potency immunogenic zika virus compositions92US 10,273,269 B2ModernaTX, Inc. · 2019
- Combination purified inactivated vaccine for flaviviruses17US 10,086,061 B2The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research · 2018
- Method of reversing immunosuppression in vaccines13US 5,928,649 AAmerican Cyanamid Company · 1999